Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme
NCT ID: NCT01174524
Last Updated: 2010-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2008-01-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause
NCT00925639
Effects of Hormone Replacement Therapy on Cardiovascular Risk and Body Composition Parameters
NCT04453332
Pilot Study to Investigate the Impact of an App on the Quality of Life and Symptoms of Individuals Affected by Menopause
NCT06987617
Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.
NCT00775242
Impact of Treatment Induced Premature Menopause on Quality of Life
NCT00185718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gestoden and ethinylestradiol
Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.
The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients.
gestoden 60 mcg
gestoden 60 mcg, once a day, administered in 24/4 regimen.
ethinylestradiol 15 mcg
ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gestoden 60 mcg
gestoden 60 mcg, once a day, administered in 24/4 regimen.
ethinylestradiol 15 mcg
ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Women in menopause
* Diseases the forbidden the use of the drug
15 Years
46 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medley S∕A Indústria Farmacêutica
UNKNOWN
Hospital Geral de Fortaleza
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hospital Geral de Fortaleza
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
joao MM Silva, PhD Student
Role: PRINCIPAL_INVESTIGATOR
Hospital Geral de Fortaleza
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Geral de Fortaleza
Fortaleza, Ceará, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MedleyHGF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.